Medication Brand Names Beginning with ‘D’

Page 1 of 513 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

D-Care 100X (Lidocaine Hydrochloride, Povidone-Iodine, Isopropyl Alcohol)

Xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional…

RX PHARMA-PACK, INC.26 October 2018

D.H.E. 45 (Dihydroergotamine Mesylate)

D.H.E. 45 (dihydroergotamine mesylate) Injection USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes…

Valeant Pharmaceuticals North America6 November 2017

D.H.E. 45 (Dihydroergotamine Mesylate)

D.H.E. 45 (dihydroergotamine mesylate) Injection USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes…

Bausch Health US, LLC6 November 2017

Dacarbazine

Dacarbazine is indicated in the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. CONTRAINDICATIONS:…

Bedford Laboratories5 May 2010

Dacarbazine

Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition. Dacarbazine for Injection is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents…

APP Pharmaceuticals, LLC4 September 2012

Page 1 of 513 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

FDA Medwatch

Precision Dose Inc. Issues Voluntary Nationwide Recall of Ranitidine Oral Solution, USP 150 mg/10 mL Due to Possible Presence of N-nitrosodimethylamine (NDMA) Impurity
Mon, 18 Nov 2019. Precision Dose Inc. is voluntarily recalling 5 lots of Ranitidine Oral Solution, USP 150 mg/10 mL to the consumer level. Ranitidine Oral Solution, USP 150 mg/10 mL, is being recalled because of potential N-Nitrosodimethylamine (NDMA) amounts above…
Update On Device Failure Associated with Getinge’s Maquet/Datascope Intra-Aortic Balloon Pumps – Letter to Health Care Providers
Mon, 18 Nov 2019. The U.S. Food and Drug Administration (FDA) is providing an update on our evaluation of device failures associated with Getinge's Maquet/Datascope intra-aortic balloon pump (IABP) devices: Cardiosave (Hybrid and Rescue), CS300 and CS100/CS100i.

MedLibrary.org

Medication Sections

RSS Feeds

About

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.